Brendan Cole

By Brendan Cole

Senior Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


The pharmaceutical company Novartis responded to criticism leveled against it on social media on Monday about the drug hydroxychloroquine and the reason the president has touted it. Novartis, the Swiss pharmaceutical company that is a major manufacturer of the drug told Newsweek the criticism was "without merit."

President Donald Trump has championed the use of hydroxychloroquine as a treatment for COVID-19. Some on social media, however, criticized Novartis, which makes the drug, saying that the drug was unproven and the company was cashing in, and claiming that Trump was pushing it because of a deal Novartis had with his former lawyer Michael Cohen.

In addition to calling the criticism "without merit," Novartis told Newsweek it was committed to donating up to 130 million doses of generic hydroxychloroquine should it prove effective in treating COVID-19. It said that its generics and biosimilars division Sandoz "intends to donate all of our HCQ inventory that is not already allocated to existing orders and customers."

Read More

Trump Says He Won’t Wear a Mask for Coronavirus—Here’s What Science Says about Masks and COVID-19 Transmission7 min read

Trump Says He Won’t Wear a Mask for Coronavirus—Here’s What Science Says about Masks and COVID-19 Transmission

On Sunday, Trump recommended the anti-malaria drug for the second day in a row, saying at a media briefing that he was optimistic about its potential to treat COVID-19 patients and that the federal government had stockpiled around 29 million pills.

It followed a report last week that the drug had hastened recovery for a small number of patients in China with COVID-19, according to The New York Times.

Last month, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to allow the use of hydroxychloroquine and another anti-malaria drug, chloroquine, for those infected by COVID-19. However, infectious disease expert and leading member of the White House Coronavirus Task Force Dr. Anthony Fauci has said that there is insufficient scientific evidence to suggest the drug can treat COVID-19.

U.S. President Donald Trump and Anthony Fauci

...

On Sunday night and Monday morning, Novartis started trending. Some referred to the company's payment of $1.2 million to Trump's former lawyer Michael Cohen for health care policy consulting work during a contract that was signed in 2017.

In 2018, Novartis said it had signed a one-year contract with Cohen's shell company, Essential Consultants, for $100,000 per month for advice on how the Trump administration might approach healthcare policy matters.

However this ended just a month into the deal after the Swiss company decided that Cohen was not able to provide "the services that Novartis had anticipated," CNBC reported.

Novartis told Newsweek it started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the U.S. Department of Health and Human Services for immediate use in controlled clinical studies.

"Our manufacturing site is working 24/7, and we are also exploring further scaling of capacity to increase supply, including working with manufacturers around the world to meet global demand," the company said.

Last month, Novartis Chief Executive Vas Narasimhan said hydroxychloroquine was his company's biggest hope against the coronavirus.

He told Swiss newspaper SonntagsZeitung that preclinical studies in animals and data from the first clinical studies "show that hydroxychloroquine kills the coronavirus," however he did note that "it's too early to say anything definitively."

Centers for Disease Control and Prevention Advice on Using Face Coverings to Slow Spread of COVID-19

World Health Organization advice for avoiding spread of coronavirus disease (COVID-19)

Hygiene advice

Medical advice

Mask and glove usage

Correction: This story and headline have been updated to more accurately reflect the criticism of Novartis and its response.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines